ClinicalTrials.gg
CompletedNCT00282295Updated Aug 17, 2018Results posted

US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease

A Phase 4 interventional study of Boostrix® and Menactra™ in Acellular Pertussis, Tetanus and Diphtheria, sponsored by GlaxoSmithKline. Completed at 24 sites in United States. Open to participants aged 11 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-17.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,344
Allocation
Randomized
Ages
11 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing boostrix in Tetanus — 2 open to participants now, 2 under way, none of them phase 3. Boostrix · Tetanus.

Enrollment
4th of 22
1,344 · median 554
Started
2006
with 3 others
Phase 4
8 of 22
none open now
Registered
1st of 22
by date
Lead sponsor
18 of 22
GlaxoSmithKline

Among the 22 studies testing boostrix in Tetanus, this one is the 4th largest by enrollment, is one of 4 that started in 2006, is one of 8 in phase 4, and was the 1st registered.

Tetanus

318 studies on the registry are indexed under Tetanus; 29 are open to participants now.

Browse Tetanus studies →

Open to participants now

2 of the 22 studies testing boostrix in Tetanus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About boostrix

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 16 Tetanus studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 11 Years to 18 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing boostrix in Tetanus, or all of them as a file.
02

Study summary

New immunization recommendations in the US include vaccination of adolescents against pertussis and meningococcal disease. The Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention recommends that Tdap (Tetanus Toxoid, Reduced Diphtheria Toxoid And Acellular Pertussis Vaccine Adsorbed) and MCV4 (Meningococcal conjugate vaccine against serotypes A, C, Y and W-135) vaccines be administered to adolescents at the same office visit if vaccination with both vaccines is indicated. Therefore, this study is designed to evaluate the safety and immunogenicity of a booster vaccination with Boostrix co-administered with Menactra as compared to the administration of either vaccine alone in healthy adolescents 11 - 18 years of age.

Read the detailed description

A phase IV, randomized, partially blinded multicenter study to evaluate the safety and immunogenicity of a booster vaccination with GlaxoSmithKline's tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed [Tdap Boostrix®] co-administered intramuscularly with Aventis-Pasteur's meningococcal (serogroups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (Menactra™) as compared to the administration of either vaccine alone in healthy adolescents 11-18 years of age. "Experimental design: Prospective, randomized, controlled multicenter study with three groups:

Group 1: Boostrix + Menactra on Day 0, blood samples at Month 0 and Month 1 Group 2: Boostrix on Day 0, Menactra at Month 1, blood samples at Month 0, Month 1, and Month 2 Group 3: Menactra on Day 0, Boostrix at Month 1, blood samples at Month 0, Month 1 and Month 2 Treatment allocation: randomized 1:1:1 Type of study: self-contained Duration of the study: Approximately one month for each subject in Group 1 and approximately two months for each subject in the Group 2 and Group 3."

03

Conditions studied

  • Acellular Pertussis
  • Tetanus
  • Diphtheria

Keywords

  • tetanus
  • pertussis
  • Prophylaxis
  • meningococcus
  • diptheria
04

Who can participate

Ages eligible
11 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects as established by medical history and history-directed physical examination before entering into the study.
  • Previously completed routine childhood vaccinations against diphtheria, tetanus and pertussis diseases according to the recommended vaccination schedule at the time.
  • Females of at the time of study entry are required to have a negative pregnancy test prior to administration of the dose of vaccine and are required to be abstinent or use adequate precautions for one month prior to vaccination. Subjects also are required to agree to continue such precautions for two months after vaccination.

Exclusion criteria

Exclusion Criteria:

  • Administration of a pre-school booster of DTP vaccine within the previous 5 years
  • Administration of a diphteria-tetanus (Td) booster within the previous 5 years
  • Previous vaccination against N. meningitidis
  • to latex
  • History of serious allergic reaction (e.g. anaphylaxis) following any other tetanus toxoid, diphteria toxoid or pertussis-containing vaccine or any component of the study vaccines
  • History of encephalopathy (e.g. coma, decreased level of consciousness, prolonged seizures) within seven days of administration of a previous dose of pertussis vaccine taht is not attributable to another identifiable cause
  • Progressive neurologic disorder, uncontrolled epilepsy or progressive encephalopathy: pertussis vaccine should not be administered to individuals with these conditions until a treatment regimen has been established and the condition has stabilized
  • Previous history of Guillain-Barré syndrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
1,344 participants (actual)

Study arms

  • Experimental
    Boostrix + Menactra Group

    Subjects, 11 through 18 years of age, received a booster dose of Boostrix® co-administered with Menactra™ at Day 0. The Boostrix® vaccine was administered intramuscularly into the left deltoid region and Menactra™ vaccine was administered intramuscularly into the right deltoid region.

    Biological: Boostrix® · Biological: Menactra™

  • Experimental
    Boostrix-Menactra Group

    Subjects, 11 through 18 years of age, received one dose of Boostrix® vaccine at Day 0, followed by one dose of Menactra™ vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.

    Biological: Boostrix® · Biological: Menactra™

  • Experimental
    Menactra-Boostrix Group

    Subjects, 11 through 18 years of age, received one dose of Menactra™ vaccine at Day 0 followed by one dose of Boostrix® vaccine at Month 1. Both vaccines were administered intramuscularly into the left deltoid region.

    Biological: Boostrix® · Biological: Menactra™

Interventions

  • BiologicalBoostrix®

    GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.

  • BiologicalMenactra™

    Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.

06

What researchers measure

Primary outcomes

  1. Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

    Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

    Time frame: At Month 1 (post Boostrix vaccination)

  2. Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

    Concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

    Time frame: At Month 1 (post Boostrix vaccination)

  3. Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

    Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

    Time frame: At Month 1 (post Boostrix vaccination)

  4. Number of Subjects With Vaccine Responses for Serum Bactericidal Assay Against Neisseria Meningitidis Serogroups A (rSBA-MenA), C (rSBA-MenC), Y (rSBA-MenY) and W-135 (rSBA-MenW-135)

    Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra vaccination; and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with Menactra vaccine.

    Time frame: One month post Boostrix vaccination ((Month 1 for Boostrix + Menactra Group and Month 2 for Menactra-Boostrix Group)

Secondary outcomes

  1. Number of Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

    Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

    Time frame: At Day 0 (PRE) before Boostrix vaccination

  2. Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

    Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

    Time frame: At Month 2 (one month post Boostrix vaccination)

  3. Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens

    Cut-off values assessed were greater than or equal to 0.1 international units per milliliter (IU/m L).

    Time frame: PRE (Day 0) and POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)

  4. Number of Subjects With Booster Responses for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

    Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 0.1 IU/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 0.4 IU/mL), one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

    Time frame: At one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)

  5. Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

    Time frame: PRE (Day 0) and one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)

  6. Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

    Time frame: At one month POST Menactra vaccination (Month 2 for Boostrix-Menactra Group and Month 1 for Menactra-Boostrix Group)

  7. Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

    Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

    Time frame: At Month 2 (one month post Boostrix vaccination)

  8. Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

    Time frame: At Day 0 before (PRE) Boostrix vaccination

  9. Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

    Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

    Time frame: At Month 2 (one month post Boostrix vaccination)

  10. Titers for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies

    Antibody titers are presented as geometric mean titers (GMTs).

    Time frame: PRE (Day 0) and one month POST Menactra vaccination (Month 2 for Boostrix + Menactra Group and Boostrix-Menactra Group / Month 1 for Menactra-Boostrix Group)

  11. Number of Subjects With Vaccine Responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies

    Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra the vaccine, and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with the Menactra vaccine.

    Time frame: At Month 2 (one month after vaccination with Menactra vaccine)

  12. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Assessed solicited local symptoms were pain, redness and swelling. Any = any solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activities. Grade 3 redness/swelling = redness/swelling with diameter ≥ 50 millimeters (mm).

    Time frame: Within 4-days (Day 0-3) after each dose and across doses

  13. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\], headache and gastrointestinal symptoms \[gastro sympt\]. Any = any solicited general symptom irrespective of intensity grade or relationship to vaccination. Grade 3 = symptoms that prevented normal activities. Grade 3 Fever = temperature higher than (\>) 39° C. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain.

    Time frame: Within 4-days (Days 0-3) after each dose and across doses

  14. Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE =An AE which prevented normal, everyday activities. Such an AE, for example, prevented attendance at work/school and necessitated the administration of corrective therapy. Related = AE assessed by the investigator as related to the vaccination.

    Time frame: Within the 31-day (Days 0-30) period after each vaccination

  15. Number of Subjects With Serious Adverse Events (SAEs)

    Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

    Time frame: Throughout the entire study period (Day 0 - Month 2)

07

Results

Posted Mar 16, 2017
Limitations and caveats
None reported.

Participant flow

Participant flow — Overall Study
MilestoneBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Started446446449
Completed443429441
Not completed3178
Withdrew: Adverse event010
Withdrew: Serious adverse events001
Withdrew: Protocol violation021
Withdrew: Withdrawal by subject264
Withdrew: Lost to follow-up172
Withdrew: Other010

Outcome measures

PrimaryNumber of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

Time frame:
At Month 1 (post Boostrix vaccination)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra Group
Anti-D427405
Anti-T425412
Statistical analysis
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Difference: 2.18 · 95% CI 0.79 to 4.17
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Difference: 0.02 · 95% CI -1.4 to 1.48
PrimaryAnti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

Concentrations were presented as geometric mean concentrations (GMCs), expressed in enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).

Time frame:
At Month 1 (post Boostrix vaccination)
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
EL.U/mLBoostrix + Menactra GroupBoostrix-Menactra Group
Anti-PT63.9 (58.6 to 69.7)74.3 (67.9 to 81.3)
Anti-FHA444.8 (415.0 to 476.7)575.8 (532.8 to 622.1)
Anti-PRN253.4 (224.8 to 285.6)366.0 (321.6 to 416.6)
Statistical analysis
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Adjusted gmc ratio: 0.93 · 95% CI 0.84 to 1.03
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Adjusted gmc ratio: 0.76 · 95% CI 0.69 to 0.84
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Adjusted gmc ratio: 0.63 · 95% CI 0.54 to 0.72
PrimaryNumber of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

Time frame:
At Month 1 (post Boostrix vaccination)
Reported as:
Count of participants · Participants
Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra Group
Anti-PT, Total322333
Anti-FHA, Total385388
Anti-PRN, Total398394
Statistical analysis
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Difference in booster response rate: -4.38 · 95% CI -9.91 to 1.15
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Difference in booster response rate: -3.39 · 95% CI -7.03 to 0.15
  • Boostrix + Menactra Group vs Boostrix-Menactra Group · Difference in booster response rate: -1.96 · 95% CI -5.25 to -1.25
PrimaryNumber of Subjects With Vaccine Responses for Serum Bactericidal Assay Against Neisseria Meningitidis Serogroups A (rSBA-MenA), C (rSBA-MenC), Y (rSBA-MenY) and W-135 (rSBA-MenW-135)

Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra vaccination; and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with Menactra vaccine.

Time frame:
One month post Boostrix vaccination ((Month 1 for Boostrix + Menactra Group and Month 2 for Menactra-Boostrix Group)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Responses for Serum Bactericidal Assay Against Neisseria Meningitidis Serogroups A (rSBA-MenA), C (rSBA-MenC), Y (rSBA-MenY) and W-135 (rSBA-MenW-135)
ParticipantsBoostrix + Menactra GroupMenactra-Boostrix Group
rSBA-MenA, Total329328
rSBA-MenC, Total390383
rSBA-MenY, Total369358
rSBA-MenW-135, Total404394
Statistical analysis
  • Boostrix + Menactra Group vs Menactra-Boostrix Group · Difference in vaccine response rate: -0.21 · 95% CI -4.85 to 4.43
  • Boostrix + Menactra Group vs Menactra-Boostrix Group · Difference in vaccine response rate: 1.69 · 95% CI -1.69 to 5.16
  • Boostrix + Menactra Group vs Menactra-Boostrix Group · Difference in vaccine response rate: 1.82 · 95% CI -2.58 to 6.25
  • Boostrix + Menactra Group vs Menactra-Boostrix Group · Difference in vaccine response rate: 3.56 · 95% CI 0.96 to 6.45
SecondaryNumber of Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

Time frame:
At Day 0 (PRE) before Boostrix vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
ANTI-D, PRE10993120
ANTI-T, PRE201181195
SecondaryNumber of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

Cut-off values assessed were greater than or equal to 1.0 international units per milliliter (IU/mL).

Time frame:
At Month 2 (one month post Boostrix vaccination)
Reported as:
Count of participants · Participants
Number of Subjects With Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
ParticipantsMenactra-Boostrix Group
Anti-D428
Anti-T426
SecondaryNumber of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens

Cut-off values assessed were greater than or equal to 0.1 international units per milliliter (IU/m L).

Time frame:
PRE (Day 0) and POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Reported as:
Count of participants · Participants
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Anti-D, PRE399383391
Anti-T, PRE423409423
ANTI-D, POST428415429
ANTI-T, POST428415429
SecondaryNumber of Subjects With Booster Responses for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies

Booster responses for anti-D and anti-T antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 0.1 IU/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥ 0.4 IU/mL), one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects (pre-vaccination concentration ≥ 0.1 IU/mL): an increase in antibody concentrations of at least four times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

Time frame:
At one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Reported as:
Count of participants · Participants
Number of Subjects With Booster Responses for Anti-diphtheria (Anti-D) and Anti-tetanus (Anti-T) Antibodies
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Anti-D, Total422377422
Anti-T, Total310330329
SecondaryAnti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

Time frame:
PRE (Day 0) and one month POST Boostrix vaccination (Month 1 for Boostrix + Menactra Group and Boostrix-Menactra Group/ Month 2 for Menactra-Boostrix Group)
Reported as:
Geometric mean · IU/mL
Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
IU/mLBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Anti-D, PRE0.5 (0.4 to 0.6)0.5 (0.4 to 0.5)0.5 (0.4 to 0.5)
Anti-D, POST40.1 (36.9 to 43.5)10.2 (9.3 to 11.2)27.3 (25.1 to 29.6)
Anti-T, PRE1.0 (0.9 to 1.1)0.8 (0.8 to 0.9)0.9 (0.8 to 1.0)
Anti-T, POST9.5 (8.9 to 10.2)12.7 (11.8 to 13.8)12.2 (11.3 to 13.2)
SecondaryAnti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).

Time frame:
At one month POST Menactra vaccination (Month 2 for Boostrix-Menactra Group and Month 1 for Menactra-Boostrix Group)
Reported as:
Geometric mean · IU/mL
Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations
IU/mLBoostrix-Menactra GroupMenactra-Boostrix Group
Anti-D16.5 (15.4 to 17.6)41.6 (38.1 to 45.5)
Anti-T10.0 (9.2 to 10.8)0.9 (0.8 to 1.0)
SecondaryNumber of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies

Booster responses for anti-PT, anti-FHA and anti-PRN antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off concentration of 5 EL.U/mL): antibody concentrations at least four times the cut-off (postvaccination concentration ≥20 EL.U/mL) one month after vaccination with the Boostrix vaccine; for initially seropositive subjects with pre-vaccination concentration ≥5 EL.U/mL and \< 20 EL.U/mL: an increase in antibody concentrations of at least four times the pre-vaccination concentration, one month after vaccination with the Boostrix vaccine; and for initially seropositive subjects with pre-vaccination concentration ≥ 20 EL.U/mL: an increase in antibody concentrations of at least two times the pre-vaccination concentration one month after vaccination with the Boostrix vaccine.

Time frame:
At Month 2 (one month post Boostrix vaccination)
Reported as:
Count of participants · Participants
Number of Subjects With Booster Responses for Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibodies
ParticipantsMenactra-Boostrix Group
Anti-PT, Total338
Anti-FHA, Total405
Anti-PRN, Total414
SecondaryAnti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

Time frame:
At Day 0 before (PRE) Boostrix vaccination
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
EL.U/mLBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Anti-PT8.6 (7.7 to 9.6)10.0 (8.9 to 11.3)10.3 (9.2 to 11.6)
Anti-FHA46.5 (41.4 to 52.3)43.8 (39.1 to 49.0)47.8 (42.4 to 53.8)
Anti-PRN12.5 (11.1 to 14.1)10.6 (9.3 to 12.0)12.0 (10.6 to 13.5)
SecondaryAnti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations

Concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL).

Time frame:
At Month 2 (one month post Boostrix vaccination)
Reported as:
Geometric mean · EL.U/mL
Anti-pertussis Toxoid (Anti-PT), Anti-filamentous Hemagglutinin (Anti-FHA) and Anti-pertactin (Anti-PRN) Antibody Concentrations
EL.U/mLMenactra-Boostrix Group
Anti-PT77.8 (71.5 to 84.6)
ANTI-FHA653.0 (603.6 to 706.5)
Anti-PRN412.5 (364.5 to 466.9)
SecondaryTiters for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies

Antibody titers are presented as geometric mean titers (GMTs).

Time frame:
PRE (Day 0) and one month POST Menactra vaccination (Month 2 for Boostrix + Menactra Group and Boostrix-Menactra Group / Month 1 for Menactra-Boostrix Group)
Reported as:
Geometric mean · Titers
Titers for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies
TitersBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
rSBA-MenA, PRE533.4 (464.6 to 612.3)490.8 (428.4 to 562.3)449.4 (383.4 to 526.6)
rSBA-MenA, POST10406.1 (9687.2 to 11178.3)7220.0 (6613.3 to 7882.4)9466.3 (8765.6 to 10222.9)
rSBA-MenC, PRE21.0 (17.2 to 25.5)16.4 (13.6 to 19.8)18.7 (15.3 to 22.8)
rSBA-MenC, POST2760.2 (2387.5 to 3191.1)1137.0 (969.6 to 1333.3)2702.8 (2292.6 to 3186.5)
rSBA-MenY, PRE53.8 (43.6 to 66.5)51.4 (41.6 to 63.5)56.2 (45.1 to 70.1)
rSBA-MenY, POST3244.2 (2884.1 to 3649.1)1470.7 (1311.4 to 1649.3)3022.8 (2687.0 to 3400.6)
rSBA-MenW-135, PRE23.7 (19.5 to 28.6)28.0 (23.1 to 34.0)32.2 (26.6 to 39.0)
rSBA-MenW-135, POST4822.1 (4351.6 to 5343.4)2143.1 (1913.9 to 2399.8)4154.3 (3690.9 to 4675.9)
SecondaryNumber of Subjects With Vaccine Responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies

Vaccine responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 antibodies were defined as: for initially seronegative subjects (pre-vaccination concentration below the cut-off titer of 8): antibody titers at least four times the cut-off (post-vaccination concentration ≥ 32) one month after vaccination with Menactra the vaccine, and for initially seropositive subjects (pre-vaccination titer ≥ 8): antibody titers at least four times the pre-vaccination antibody titers, one month after vaccination with the Menactra vaccine.

Time frame:
At Month 2 (one month after vaccination with Menactra vaccine)
Reported as:
Count of participants · Participants
Number of Subjects With Vaccine Responses for rSBA-MenA, rSBA-MenC, rSBA-MenY and rSBA-MenW-135 Antibodies
ParticipantsBoostrix-Menactra Group
rSBA-MenA, Total300
rSBA-MenC, Total351
rSBA-MenY, Total325
rSBA-MenW-135, Total360
SecondaryNumber of Subjects With Any and Grade 3 Solicited Local Symptoms

Assessed solicited local symptoms were pain, redness and swelling. Any = any solicited local symptom irrespective of intensity grade. Grade 3 pain = pain that prevented normal activities. Grade 3 redness/swelling = redness/swelling with diameter ≥ 50 millimeters (mm).

Time frame:
Within 4-days (Day 0-3) after each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Pain, Any, Dose 1331304236
Pain, Grade 3, Dose 126146
Redness, Any, Dose 111811184
Redness, ≥ 50 mm, Dose 11014
Swelling, Any, Dose 1997856
Swelling, ≥ 50 mm, Dose 1875
Pain, Any, Dose 2NA260211
Pain, Grade 3, Dose 2NA134
Redness, Any, Dose 2NA8579
Redness, ≥ 50 mm, Dose 2NA82
Swelling, Any, Dose 2NA6453
Swelling, ≥ 50 mm, Dose 2NA93
Pain, Any, Across doses331343291
Pain, Grade 3, Across doses26269
Redness, Any, Across doses118141119
Redness, ≥ 50 mm, Across doses1086
Swelling, Any, Across doses9910584
Swelling, ≥ 50 mm, Across doses8138
SecondaryNumber of Subjects With Any, Grade 3 and Related Solicited General Symptoms

Assessed solicited general symptoms were fatigue, fever \[defined as oral temperature equal to or above 37.5 degrees Celsius (°C)\], headache and gastrointestinal symptoms \[gastro sympt\]. Any = any solicited general symptom irrespective of intensity grade or relationship to vaccination. Grade 3 = symptoms that prevented normal activities. Grade 3 Fever = temperature higher than (\>) 39° C. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Gastrointestinal symptoms included nausea, vomiting, diarrhea and/or abdominal pain.

Time frame:
Within 4-days (Days 0-3) after each dose and across doses
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Fatigue, Any, Dose 1150139114
Fatigue, Grade 3, Dose 11395
Fatigue, Related, Dose 112011386
Fever (orally), Any, Dose 1231521
Fever (orally), Grade 3, Dose 1210
Fever (orally), Related, Dose 120816
Gastro sympt., Any, Dose 1676360
Gastro sympt, Grade 3, Dose 1442
Gastro sympt, Related, Dose 1464136
Headache, Any, Dose 1150133116
Headache, Grade 3, Dose 112127
Headache, Related, Dose 112710485
Fatigue, Any, Dose 2NA10390
Fatigue, Grade 3, Dose 2NA53
Fatigue, Related, Dose 2NA8370
Fever (orally), Any, Dose 2NA1410
Fever (orally), Grade 3, Dose 2NA11
Fever (orally), Related, Dose 2NA99
Gastro sympt., Any, Dose 2NA4634
Gastro sympt., Grade 3, Dose 2NA13
Gastro sympt., Related, Dose 2NA3224
Headache, Any, Dose 2NA9575
Headache, Grade 3, Dose 2NA22
Headache, Related, Dose 2NA7256
Fatigue, Any, Across150175160
Fatigue, Grade 3, Across13137
Fatigue, Related, Across120146128
Fever (orally), Any, Across232829
Fever (orally), Grade 3, Across221
Fever (orally), Related, Across201623
Gastro sympt., Any, Across679680
Gastro sympt., Grade 3, Across455
Gastro sympt., Related, Across466554
Headache, Any, Across150177157
Headache, Grade 3, Across12139
Headache, Related, Across127142121
SecondaryNumber of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE =An AE which prevented normal, everyday activities. Such an AE, for example, prevented attendance at work/school and necessitated the administration of corrective therapy. Related = AE assessed by the investigator as related to the vaccination.

Time frame:
Within the 31-day (Days 0-30) period after each vaccination
Reported as:
Count of participants · Participants
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Any AEs124149155
Grade 3 AEs161522
Related AEs374429
SecondaryNumber of Subjects With Serious Adverse Events (SAEs)

Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Time frame:
Throughout the entire study period (Day 0 - Month 2)
Reported as:
Count of participants · Participants
Number of Subjects With Serious Adverse Events (SAEs)
ParticipantsBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Number of Subjects With Serious Adverse Events (SAEs)101

Adverse events

Collected over Solicited local and general symptoms during the 4-day (Day 0-3) follow-up period, unsolicited AEs during the 31-day (Day 0-30) follow-up period after each vaccination and SAEs throughout the study (Day 0 - Month 2).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Boostrix + Menactra Group—1/446 (0.2%)371/446 (83.2%)
Boostrix-Menactra Group—0/446 (0%)385/446 (86.3%)
Menactra-Boostrix Group—1/449 (0.2%)358/449 (79.7%)
Most frequent serious events
Most frequent serious events
EventBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
Extradural hematomaInjury, poisoning and procedural complications1/4460/4460/449
Facial bones fractureInjury, poisoning and procedural complications1/4460/4460/449
LeukemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/4460/4461/449
Most frequent other events
Most frequent other events
EventBoostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix Group
PainGeneral disorders331/446343/446291/449
HeadacheGeneral disorders150/446177/446157/449
FatigueGeneral disorders150/446175/446160/449
RednessGeneral disorders118/446141/446119/449
SwellingGeneral disorders99/446105/44684/449
Gastrointestinal symptomsGeneral disorders67/44696/44680/449
Fever (orally)General disorders23/44628/44629/449

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Boostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix GroupTotal
Mean13.5 ± 2.3113.2 ± 2.0713.4 ± 2.2713.37 ± 2.22
Sex: Female, Male
Sex: Female, Male(Participants)Boostrix + Menactra GroupBoostrix-Menactra GroupMenactra-Boostrix GroupTotal
Female210233223666
Male236213226675
08

Study locations

24 sites
  • GSK Investigational Site
    Chandler, Arizona 85224, United States
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Golden, Colorado 80401, United States
  • GSK Investigational Site
    Marietta, Georgia 30062, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Annapolis, Maryland 21401, United States
  • GSK Investigational Site
    Frederick, Maryland 21702, United States
  • GSK Investigational Site
    Omaha, Nebraska 68178, United States
  • GSK Investigational Site
    Whitehouse Station, New Jersey 08889, United States
  • GSK Investigational Site
    Pittsford, New York 14534, United States
  • GSK Investigational Site
    Rochester, New York 14620, United States
  • GSK Investigational Site
    Akron, Ohio 44308-1062, United States
  • GSK Investigational Site
    University Heights, Ohio 44118, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16505, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Greenville, Pennsylvania 16125, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15227, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Temple, Texas 76508, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84109, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    West Jordan, Utah 84084, United States
09

References and documents

Publications

  • Friedland et al. Immunogenicity of coadministered Tdap and MCV4 vaccines compared to separately administered vaccines. Accepted for poster presentation at ICAAC 2007
  • Weston et al. Reactogenicity of concomitant and separately administered Tdap and MCV4 vaccines. Accepted for poster presentation at ICAAC 2007
  • Weston WM, Friedland LR, Wu X, Howe B. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration. Vaccine. 2011 Jan 29;29(5):1017-22. doi: 10.1016/j.vaccine.2010.11.057. Epub 2010 Dec 4. PubMed 21134450 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2006 to primary completion in Aug 2006, 6 months.

Results were first posted in Mar 2017, 10 years 7 months after primary completion.

Of 19 phase 4 interventional studies under Tetanus, half reached primary completion within 22 months of starting (the median); a quarter within 6 and three quarters within 30. This study's 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2006
First posted
Jan 26, 2006
StartActual
Jan 25, 2006
Primary completionActual
Aug 8, 2006
CompletionActual
Aug 8, 2006
Results first posted
Mar 16, 2017
Last update
Aug 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00282295
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 26, 2006
Start date
Jan 25, 2006
Primary completion
Aug 8, 2006
Completion
Aug 8, 2006
Results posted
Mar 16, 2017
Last update
Aug 17, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boostrix

Start the discussion